Thus, our studies suggest that there is bi-directional interaction between T cell acute lymphoblastic leukemia/lymphoma cells and stromal cells in a tumor microenvironment and that targeting senescent stromal cells or miRNAs modulating BRCA1 and MMR pathways might prove beneficial in T-ALL/LBL patients. The gene discussed is BRCA1; the disease is lymphoma.